Pipeline
Overview
Mission Therapeutics is developing a rich pipeline of first-in-class small molecule DUB inhibitors for a number of significant clinical indications.
Pipeline
Mission Therapeutics is developing a rich pipeline of first-in-class small molecule DUB inhibitors for a number of significant clinical indications.
Our world-leading drug discovery and development platform gives us the opportunity to explore multiple additional DUB targets of relevance to other disease indications, both in-house and through partnerships with other pharmaceutical companies.
Several of our USP30 inhibitor programs are either in the clinic or approaching clinical development.
Program | Discovery | Preclinical | Phase I | Phase II | Phase III |
---|---|---|---|---|---|
CKD, HF, MD and IPF
USP30 (MTX652) | 100 | 100 | 50 | ||
PD and PMD
USP30 (MTX325) | 100 | 50 | |||
Oncology
USP21 | 75 | ||||
Fibrosis
UCHL1 | 50 | ||||
Oncology/DDR
USP47/USP37 | 50 | ||||
Oncology
JOSD1 | 50 | ||||
Oncology/Inflammation
USP25 | 50 | ||||
Neurodegeneration
MINDY2/USP47 | 50 |
Scroll pipeline to left or right
Program | Discovery | Preclinical | Phase I | Phase II | Phase III |
---|---|---|---|---|---|
Alzheimer’s & Parkinson’s disease
2 x DUBs | 50 | ||||
Anti-viral DUBs
Undisclosed | 50 |
Scroll pipeline to left or right
Research | Preclinical | Phase I |
---|
DUB program: USP30 Inhibitor
Rationale/target: Increased mitophagy
Therapeutic indication: Acute Kidney Injury
DUB program: USP30 Inhibitor
Rationale/target: Increased mitophagy
Therapeutic indication: Idiopathic Pulmonary Fibrosis
DUB program: USP30 Inhibitor
Rationale/target: Increased mitophagy
Therapeutic indication: Familial Parkinson’s Disease / Mitochondrial Disease
DUB program: DUB X
Rationale/target: Undisclosed
Therapeutic indication: Undisclosed
Research | Preclinical | Phase I |
---|
DUB program: AbbVie collaboration
Rationale/target: Undisclosed
Therapeutic indication: Alzheimer’s and Parkinson’s
Development stage: Undisclosed
DUB program: Pfizer collaboration
Rationale/target: Undisclosed
Therapeutic indication: Undisclosed
Development stage: Undisclosed